News

Dizal Highlights Its Advances in Hematological Portfolio at 2023 ASH, Featuring Breakthroughs in Lymphoma Treatment

SHANGHAI–(BUSINESS WIRE)–Dizal announces it will have 4 presentations from its hematological oncology pipeline, including golidocitinib and DZD8586, at 2023 ASH, San Diego. Click here to view original post Click here to view San Diego Biotech […]

News

Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

LA JOLLA, Calif.–(BUSINESS WIRE)—- $LBPH #Epilepsy–Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the third […]

News

Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview

SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2023. “In the third quarter, Acadia delivered record product revenue, underscoring the continued strong launch of […]

News

Going Viral

Rommie Amaro, professor of molecular biology at UC San Diego, and her team use computers to investigate biological systems. Last year, their atomic-level computational model of the H1N1 influenza virus revealed vulnerabilities that could lead […]

No Picture
News

New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate

BOTHELL, Wash.–(BUSINESS WIRE)– #ASH23–Seagen Inc. (NASDAQ: SGEN) today announced that 12- and 24-month progression free survival data will be presented for an ADCETRIS® (brentuximab vedotin) and immunotherapy combination in early and advanced stage classical Hodgkin […]

News

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

SAN DIEGO, Nov. 2, 2023 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the […]

No Picture
News

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SAN DIEGO, Nov. 2, 2023 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced the dosing of […]